Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-Magnitude of Clinical Benefit Scale: Scale Evaluation Forms v1.0 & v1.1

The ESMO-Magnitude of Clinical Benefit Scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from anti-cancer treatments.

In 2015 ESMO launched the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) to  facilitate  improved  decision-making  regarding  the  value  of  anti-cancer  therapies,  promote  the  accessibility and reduce iniquity of access to high value cancer treatments. In 2017, ESMO launched a revised version of the scale, ESMO-MCBS v 1.1.

The forms and instructions for both versions are freely accessible and downloadable.

The highest grade of the ESMO-MCBS is A in the curative setting and this is restricted to new curative treatments with a grade B also to be considered to trigger rapid reimbursement.

For non-curative indications 5 is the highest possible grade with 4 also to be considered to trigger rapid consideration for reimbursement.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings